{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:13:02Z","timestamp":1790806382649,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Various pathologies are characterized by the accumulation of toxic iron in cell compartments. In anemia of chronic disease, iron is withheld by macrophages, leaving extracellular fluids iron-depleted. In Friedreich ataxia, iron levels rise in the mitochondria of excitable cells but decrease in the cytosol. We explored the possibility of using deferiprone, a membrane-permeant iron chelator in clinical use, to capture labile iron accumulated in specific organelles of cardiomyocytes and macrophages and convey it to other locations for physiologic reuse. Deferiprone's capacity for shuttling iron between cellular organelles was assessed with organelle-targeted fluorescent iron sensors in conjunction with time-lapse fluorescence microscopy imaging. Deferiprone facilitated transfer of iron from extracellular media into nuclei and mitochondria, from nuclei to mitochondria, from endosomes to nuclei, and from intracellular compartments to extracellular apotransferrin. Furthermore, it mobilized iron from iron-loaded cells and donated it to preerythroid cells for hemoglobin synthesis, both in the presence and in the absence of transferrin. These unique properties of deferiprone underlie mechanistically its capacity to alleviate iron accumulation in dentate nuclei of Friedreich ataxia patients and to donate tissue-chelated iron to plasma transferrin in thalassemia intermedia patients. Deferiprone's shuttling properties could be exploited clinically for treating diseases involving regional iron accumulation.<\/jats:p>","DOI":"10.1182\/blood-2007-07-102335","type":"journal-article","created":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T20:48:23Z","timestamp":1193950103000},"page":"1690-1699","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":152,"title":["Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications"],"prefix":"10.1182","volume":"111","author":[{"given":"Yang-Sung","family":"Sohn","sequence":"first","affiliation":[{"name":"Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Safra Campus at Givat Ram, Jerusalem, Israel; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Breuer","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Safra Campus at Givat Ram, Jerusalem, Israel; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Munnich","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Medical Genetic Clinic and Research Unit, Inserm Unite 781, H\u00f4pital Necker-Enfants-Malades and Universit\u00e9 Paris V Ren\u00e9 Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Ioav","family":"Cabantchik","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Safra Campus at Givat Ram, Jerusalem, Israel; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111721094723500_B1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1196\/annals.1345.015","article-title":"Objectives and mechanism of iron chelation therapy.","volume":"1054","author":"Hershko","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"2019111721094723500_B2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2004.04946.x","article-title":"Purging iron from the heart.","volume":"125","author":"Hershko","year":"2004","journal-title":"Br J Haematol"},{"key":"2019111721094723500_B3","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2004-10-3856","article-title":"Iron trafficking in the mitochondrion: novel pathways revealed by disease.","volume":"105","author":"Napier","year":"2005","journal-title":"Blood"},{"key":"2019111721094723500_B4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.spen.2006.08.005","article-title":"Iron dysregulation in Friedreich ataxia.","volume":"13","author":"Wilson","year":"2006","journal-title":"Semin Pediatr Neurol"},{"key":"2019111721094723500_B5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.spen.2006.08.007","article-title":"Neurodegeneration with brain iron accumulation: from genes to pathogenesis.","volume":"13","author":"Hayflick","year":"2006","journal-title":"Semin Pediatr Neurol"},{"key":"2019111721094723500_B6","first-page":"286","article-title":"Neurodegeneration with brain iron accumulation.","volume":"43","author":"Gregory","year":"2005","journal-title":"Folia Neuropathol"},{"key":"2019111721094723500_B7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/pbc.20656","article-title":"Molecular pathogenesis of anemia of chronic disease.","volume":"46","author":"Ganz","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"2019111721094723500_B8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"2019111721094723500_B9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease.","volume":"352","author":"Weiss","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111721094723500_B10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1201\/9780824744175.ch13","article-title":"Iron chelator chemistry.","volume-title":"Molecular and Cellular Iron Transport","author":"Liu","year":"2002"},{"key":"2019111721094723500_B11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.V97.3.792","article-title":"Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.","volume":"97","author":"Breuer","year":"2001","journal-title":"Blood"},{"key":"2019111721094723500_B12","first-page":"19","article-title":"The effect of alpha-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo.","volume":"28","author":"Evans","year":"1992","journal-title":"Drugs Today (Barc)"},{"key":"2019111721094723500_B13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia. Biological and clinical implications.","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"2019111721094723500_B14","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/0006-2952(93)90222-I","article-title":"Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo.","volume":"45","author":"Waldmeier","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"2019111721094723500_B15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0006-2952(99)00031-3","article-title":"Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability.","volume":"57","author":"Habgood","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"2019111721094723500_B16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0300-483X(95)03301-U","article-title":"The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1\u2032ol]-2-methyl-3-hydroxypyridin-4-one in the rat.","volume":"108","author":"Fredenburg","year":"1996","journal-title":"Toxicology"},{"key":"2019111721094723500_B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1201\/9780824744175.pt1","article-title":"Iron chemistry.","volume-title":"Molecular and Cellular Iron Transport","author":"Harris","year":"2002"},{"key":"2019111721094723500_B18","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.274.19.13375","article-title":"Calcein as a fluorescent probe for ferric iron. Application to iron nutrition in plant cells.","volume":"274","author":"Thomas","year":"1999","journal-title":"J Biol Chem"},{"key":"2019111721094723500_B19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0003-2697(90)90088-Q","article-title":"A direct method for quantification of non-transferrin-bound iron.","volume":"186","author":"Singh","year":"1990","journal-title":"Anal Biochem"},{"key":"2019111721094723500_B20","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood-2005-02-0460","article-title":"Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.","volume":"106","author":"Glickstein","year":"2005","journal-title":"Blood"},{"key":"2019111721094723500_B21","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2006-05-020867","article-title":"Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences.","volume":"108","author":"Glickstein","year":"2006","journal-title":"Blood"},{"key":"2019111721094723500_B22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/bj3620137","article-title":"Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor.","volume":"362","author":"Petrat","year":"2002","journal-title":"Biochem J"},{"key":"2019111721094723500_B23","doi-asserted-by":"crossref","first-page":"C1383","DOI":"10.1152\/ajpcell.00054.2007","article-title":"Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications.","volume":"293","author":"Shvartsman","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"2019111721094723500_B24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1042\/BA20050063","article-title":"Nuclear proteins as gene-transfer vectors.","volume":"42","author":"Haberland","year":"2005","journal-title":"Biotechnol Appl Biochem"},{"key":"2019111721094723500_B25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1042\/bj3540423","article-title":"Spectral and metal binding properties of three single-point tryptophan mutants of the human transferring N-lobe.","volume":"354","author":"He","year":"2001","journal-title":"Biochem J"},{"key":"2019111721094723500_B26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/stem.5530060402","article-title":"Hexamethylene bis-acetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application.","volume":"6","author":"Marks","year":"1988","journal-title":"Int J Cell Cloning"},{"key":"2019111721094723500_B27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.2007.06549.x","article-title":"Iron deprivation blocks multilineage haematopoietic differentiation by inhibiting induction of p21(WAF1\/CIP1).","volume":"137","author":"Alcantara","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111721094723500_B28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/clinchem\/33.2.273","article-title":"Plasma iron and transferrin iron-binding capacity evaluated by colorimetric and immunoprecipitation methods.","volume":"33","author":"Huebers","year":"1987","journal-title":"Clin Chem"},{"key":"2019111721094723500_B29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1471-4159.1997.69020443.x","article-title":"Transport of iron in the blood-brain-cerebrospinal fluid system.","volume":"69","author":"Bradbury","year":"1997","journal-title":"J Neurochem"},{"key":"2019111721094723500_B30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/(SICI)1097-4547(19981115)54:4<486::AID-JNR6>3.0.CO;2-I","article-title":"Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid.","volume":"54","author":"Moos","year":"1998","journal-title":"J Neurosci Res"},{"key":"2019111721094723500_B31","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2005-08-3364","article-title":"Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease.","volume":"107","author":"Theurl","year":"2006","journal-title":"Blood"},{"key":"2019111721094723500_B32","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1039\/an9952000845","article-title":"New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators.","volume":"120","author":"Kontoghiorghes","year":"1995","journal-title":"Analyst"},{"key":"2019111721094723500_B33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.spen.2006.08.008","article-title":"Iron: a new target for pharmacological intervention in neurodegenerative diseases.","volume":"13","author":"Whitnall","year":"2006","journal-title":"Semin Pediatr Neurol"},{"key":"2019111721094723500_B34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.rmr.0000245461.90406.ad","article-title":"Role of iron in neurodegenerative disorders.","volume":"17","author":"Berg","year":"2006","journal-title":"Top Magn Reson Imaging"},{"key":"2019111721094723500_B35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.spen.2006.08.002","article-title":"Brain iron metabolism.","volume":"13","author":"Rouault","year":"2006","journal-title":"Semin Pediatr Neurol"},{"key":"2019111721094723500_B36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1124\/mol.51.5.842","article-title":"Chelation and mobilization of cellular iron by different classes of chelators.","volume":"51","author":"Zanninelli","year":"1997","journal-title":"Mol Pharmacol"},{"key":"2019111721094723500_B37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1067\/mlc.2001.116487","article-title":"Exploring the \u201ciron shuttle\u201d hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.","volume":"138","author":"Link","year":"2001","journal-title":"J Lab Clin Med"},{"key":"2019111721094723500_B38","article-title":"Intracellular labile iron.","author":"Breuer","journal-title":"Int J Biochem Cell Biol"},{"key":"2019111721094723500_B39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mrfmmm.2003.08.004","article-title":"Labile iron pool: The main determinant of cellular response to oxidative stress.","volume":"29","author":"Kruszewski","year":"2003","journal-title":"Mutat Res"},{"key":"2019111721094723500_B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/abio.2002.5611","article-title":"A review of fluorescence methods for assessing labile iron in cells and biological fluids.","volume":"304","author":"Esp\u00f3sito","year":"2002","journal-title":"Anal Biochem"},{"key":"2019111721094723500_B41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.bi.49.070180.002041","article-title":"Iron transport and storage proteins.","volume":"49","author":"Aisen","year":"1980","journal-title":"Annu Rev Biochem"},{"key":"2019111721094723500_B42","article-title":"The Fenton activity of iron(III) in the presence of deferiprone.","author":"Devanur","journal-title":"J Pharm Sci"},{"key":"2019111721094723500_B43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/jcp.1041460317","article-title":"Ferric-salicylaldehyde isonicotinoyl hydrazone, a synthetic iron chelate, alleviates defective iron utilization by reticulocytes of the Belgrade rat.","volume":"146","author":"Garrick","year":"1991","journal-title":"J Cell Physiol"},{"key":"2019111721094723500_B44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/bss0610127","article-title":"Therapeutic iron chelators and their potential side-effects.","volume":"61","author":"Singh","year":"1995","journal-title":"Biochem Soc Symp"},{"key":"2019111721094723500_B45","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood-2003-03-0807","article-title":"Labile plasma iron in iron overload: redox activity and susceptibility to chelation.","volume":"102","author":"Esposito","year":"2003","journal-title":"Blood"},{"key":"2019111721094723500_B46","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/blood-2002-08-2459","article-title":"Cytokine-mediated regulation of iron transport in human monocytic cells.","volume":"101","author":"Ludwiczek","year":"2003","journal-title":"Blood"},{"key":"2019111721094723500_B47","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/ard.49.11.956-b","article-title":"Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis.","volume":"49","author":"Vreugdenhil","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"2019111721094723500_B48","first-page":"25","article-title":"Iron and the anemia of chronic disease.","volume":"16","author":"Spivak","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"2019111721094723500_B49","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0140-6736(89)92011-4","article-title":"Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients [letter].","volume":"2","author":"Vreugdenhil","year":"1989","journal-title":"Lancet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/3\/1690\/1309120\/zh800308001690.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/3\/1690\/1309120\/zh800308001690.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T15:45:06Z","timestamp":1588002306000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/3\/1690\/25574\/Redistribution-of-accumulated-cell-iron-a-modality"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-07-102335","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}